Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The global randomized, double-blind, placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa and Latin America.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
May 27, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022